Shots:
- Roche has reported the P-III (INShore) trial findings assessing Gazyva (Obinutuzumab; Wk. 0, 2, 24 & 26) vs mycophenolate mofetil (MMF; QD) in 85 pts (>2-25yrs.) with frequently relapsing or steroid-dependent nephrotic syndrome
- Trial met its 1EP, with more pts achieving sustained complete remission at 1yr., & certain 2EPs. Gazyva showed significant benefits in 2EPs, incl. overall RFS, median time to relapse or death, cumulative corticosteroid dose reduction, & fewer relapses by 52wks; Other 2EPs showed no significant difference
- Gazyva is being studied in membranous nephropathy, lupus nephritis, rare immune-mediated kidney diseases, and systemic lupus erythematosus, with potential EC approval for lupus nephritis expected in the future
Ref: Roche | Image: Roche | Press Release
Related News:- Roche’s Elecsys pTau181 Test Receives the US FDA’s Clearance to Rule Out Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
